Skip to content
PaperFren

Innate immunity

How do E. coli vesicles talk to gut epithelium?

Cañas MA, Fábrega MJ, Giménez R, et al. · Frontiers in microbiology · 2018

Open access · cc by · source: Europe PMC

Outer membrane vesicles from probiotic and commensal E. coli deliver ligands that activate NOD1-mediated immune responses in intestinal epithelial cells.

Study at a glance

Design
Animal / in-vitro — OMVs from probiotic/commensal E. coli tested on intestinal epithelial innate sensors (NOD1)
N
Caco-2/HT-29 cell assays — no single primary analytic N
Population
Human intestinal epithelial cell lines exposed to E. coli OMVs
Outcome
NOD1-dependent epithelial innate responses to bacterial OMVs

Structured fields used in claim comparison tables when every cited study has a complete layer.

Key findings

OMVs carry PRR ligands (e.g., PG for NOD1/NOD2) enabling bacteria–host communication across mucus; they modulate epithelial innate responses and barrier functions.

Methodology

Studied OMVs from probiotic/commensal E. coli and their interactions with intestinal epithelial innate sensors, focusing on NOD1 pathways.

Limitations

Cell/epithelial mechanism is not a full clinical probiotic trial in patients.

How this study connects

Role on claims

Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.

  • SupportsInnate immunityconcept

    OMVs carry PRR ligands (e.g., PG for NOD1/NOD2) enabling bacteria–host communication across mucus; they modulate epithelial innate responses and barrier functions.

    Evidence for the claim as stated.

  • SupportsConfocal Microscopymethod

    Probiotic and commensal E. coli OMVs carry peptidoglycan ligands for NOD1/NOD2 and modulate epithelial innate responses and barrier function across mucus. Imaging of vesicle–epithelium contact supports a communication route; it is not a full clinical probiotic trial.

    Evidence for the claim as stated.

  • SupportsConfocal Microscopymethod

    Confocal is used here for polarity reversal (enteroids), plasmodesmal targeting (PDLP), and vesicle itineraries (Bt OMVs in ~15 min; E. coli OMVs to NOD sensors). Those are different spatial questions — which face of an epithelium, which plant cell-wall channel, which endocytic route — and cannot be pooled as one 'trafficking phenotype'.

    Evidence for the claim as stated.

  • SupportsELISAmethod

    Outer-membrane vesicles from probiotic and commensal E. coli carry peptidoglycan ligands for NOD1/NOD2, enabling bacteria–host communication across mucus and modulating epithelial innate responses and barrier functions. Cytokine ELISA is a common supporting readout for those epithelial responses, but the paper is a vesicle–PRR mechanism study, not a clinical probiotic trial and not an ELISA-methods paper.

    Evidence for the claim as stated.

  • SupportsELISAmethod

    The three tagged studies disagree about what an 'ELISA paper' would even be measuring. MC4R work is cellular receptor trafficking and cAMP/ERK; MDV work is shedding, infectious period (~2 weeks) and sentinel timing (~9 days earlier) in chickens; E. coli OMV work is NOD1/NOD2 ligands and epithelial barrier signalling. They share an immunoassay-shaped supporting assay at most, not a common antigen.

    Evidence for the claim as stated.

  • SupportsELISAmethod

    Implications also conflict if someone treats every plate assay as the same. A normal cAMP well for an MC4R variant can hide a trafficking defect relevant to obesity genetics; a high viral titre after leaky vaccination can hide increased transmission of hyperpathogenic MDV; an epithelial cytokine bump after OMVs is not probiotic efficacy in patients.

    Evidence for the claim as stated.

Open questions

Tensions this paper is part of

From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.

  • Scope difference — different assays, populations, or outcomes

    Confocal is used here for polarity reversal (enteroids), plasmodesmal targeting (PDLP), and vesicle itineraries (Bt OMVs in ~15 min; E. coli OMVs to NOD sensors). Those are different spatial questions — which face of an epithelium, which plant cell-wall channel, which endocytic route — and cannot be pooled as one 'trafficking phenotype'.

  • Scope difference — different assays, populations, or outcomes

    SupportsELISA

    The three tagged studies disagree about what an 'ELISA paper' would even be measuring. MC4R work is cellular receptor trafficking and cAMP/ERK; MDV work is shedding, infectious period (~2 weeks) and sentinel timing (~9 days earlier) in chickens; E. coli OMV work is NOD1/NOD2 ligands and epithelial barrier signalling. They share an immunoassay-shaped supporting assay at most, not a common antigen.

  • Scope difference — different assays, populations, or outcomes

    SupportsELISA

    Implications also conflict if someone treats every plate assay as the same. A normal cAMP well for an MC4R variant can hide a trafficking defect relevant to obesity genetics; a high viral titre after leaky vaccination can hide increased transmission of hyperpathogenic MDV; an epithelial cytokine bump after OMVs is not probiotic efficacy in patients.

Related papers in this topic

Same topic cluster — not a recommendation engine.